NCT05188118View on ClinicalTrials.gov

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

60mg oral once daily for 12 weeks

DRUG

Ipilimumab

1mg/kg intravenous once every 3 weeks over 12 weeks

DRUG

Nivolumab

3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after

DRUG

Lenvatinib

18mg oral once daily for 12 weeks

DRUG

Everolimus

5mg oral once daily for 12 weeks

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER